Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TSN-084 by Tyligand Biotechnology (Shanghai) for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
TSN-084 is under clinical development by Tyligand Biotechnology (Shanghai) and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According...
TSN-084 by Tyligand Biotechnology (Shanghai) for Non-Small Cell Lung Cancer: Likelihood of Approval
TSN-084 is under clinical development by Tyligand Biotechnology (Shanghai) and currently in Phase I for Non-Small Cell Lung Cancer. According...
TSN-084 by Tyligand Biotechnology (Shanghai) for Solid Tumor: Likelihood of Approval
TSN-084 is under clinical development by Tyligand Biotechnology (Shanghai) and currently in Phase I for Solid Tumor. According to GlobalData,...